Home > Publications database > An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma. > print

001     182715
005     20240229145728.0
024 7 _ |a 10.1038/s41419-022-05421-4
|2 doi
024 7 _ |a pmid:36400754
|2 pmid
024 7 _ |a altmetric:138609175
|2 altmetric
037 _ _ |a DKFZ-2022-02873
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Darawshi, Odai
|b 0
245 _ _ |a An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma.
260 _ _ |a London [u.a.]
|c 2022
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1669037569_9222
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Multiple myeloma (MM) causes approximately 20% of deaths from blood cancers. Notwithstanding significant therapeutic progress, such as with proteasome inhibitors (PIs), MM remains incurable due to the development of resistance. mTORC1 is a key metabolic regulator, which frequently becomes dysregulated in cancer. While mTORC1 inhibitors reduce MM viability and synergize with other therapies in vitro, clinically, mTORC1 inhibitors are not effective for MM. Here we show that the inactivation of mTORC1 is an intrinsic response of MM to PI treatment. Genetically enforced hyperactivation of mTORC1 in MM was sufficient to compromise tumorigenicity in mice. In vitro, mTORC1-hyperactivated MM cells gained sensitivity to PIs and hypoxia. This was accompanied by increased mitochondrial stress and activation of the eIF2α kinase HRI, which initiates the integrated stress response. Deletion of HRI elevated the toxicity of PIs in wt and mTORC1-activated MM. Finally, we identified the drug PMA as a robust inducer of mTORC1 activity, which synergized with PIs in inducing MM cell death. These results help explain the clinical inefficacy of mTORC1 inhibitors in MM. Our data implicate mTORC1 induction and/or HRI inhibition as pharmacological strategies to enhance MM therapy by PIs.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Muz, Barbara
|b 1
700 1 _ |a Naamat, Shiri Gershon
|b 2
700 1 _ |a Praveen, Bellam
|b 3
700 1 _ |a Mahameed, Mohamed
|b 4
700 1 _ |a Goldberg, Karin
|b 5
700 1 _ |a Dipta, Priya
|b 6
700 1 _ |a Shmuel, Miriam
|b 7
700 1 _ |a Forno, Francesca
|b 8
700 1 _ |a Boukeileh, Shatha
|0 0000-0003-0202-4906
|b 9
700 1 _ |a Pahima, Hadas
|b 10
700 1 _ |a Hermann, Julia
|0 P:(DE-He78)ef011d4044908051e4d6f0c96e150106
|b 11
|u dkfz
700 1 _ |a Raab, Marc S
|b 12
700 1 _ |a Poos, Alexandra M
|b 13
700 1 _ |a Weinhold, Niels
|b 14
700 1 _ |a Rosenbluh, Chaggai
|b 15
700 1 _ |a Gatt, Moshe E
|b 16
700 1 _ |a Palm, Wilhelm
|0 P:(DE-He78)c8525dbb77cddc5280375ea4a5e3c13e
|b 17
|u dkfz
700 1 _ |a Azab, Abdel Kareem
|0 0000-0002-6371-2780
|b 18
700 1 _ |a Tirosh, Boaz
|0 0000-0001-8067-6577
|b 19
773 _ _ |a 10.1038/s41419-022-05421-4
|g Vol. 13, no. 11, p. 969
|0 PERI:(DE-600)2541626-1
|n 11
|p 969
|t Cell death & disease
|v 13
|y 2022
|x 2041-4889
909 C O |o oai:inrepo02.dkfz.de:182715
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)ef011d4044908051e4d6f0c96e150106
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)c8525dbb77cddc5280375ea4a5e3c13e
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-03
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-03
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CELL DEATH DIS : 2021
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-14T16:18:53Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-14T16:18:53Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-02-14T16:18:53Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CELL DEATH DIS : 2021
|d 2022-11-17
920 1 _ |0 I:(DE-He78)A330-20160331
|k A330
|l A330 NWG Signaltransduktion und Stoffwechsel der Zelle
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A330-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21